A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D
Latest Information Update: 22 Oct 2022
Price :
$35 *
At a glance
- Drugs Afimoxifene (Primary)
- Indications Hyperplasia
- Focus Registrational; Therapeutic Use
- Acronyms 4WARD
- Sponsors BHR Pharma
- 27 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 08 May 2019 Planned End Date changed from 31 Mar 2019 to 31 May 2019.
- 08 May 2019 Planned primary completion date changed from 31 Mar 2019 to 31 May 2019.